Biomarkers and Underlying Pathways for Prediction of Response to Vedolizumab Therapy in Inflammatory Bowel Disease

Vedolizumab is a humanized monoclonal antibody and one of the safest biologics for the treatment of both forms of inflammatory bowel disease (IBD)-Crohn’s disease and ulcerative colitis. It targets the α4β7 integrin and b... | Find, read and cite all the research you need on Tech Science Press